mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-CTC-3155mimmun-3155Research ArticleОБЗОРЫREVIEWSCAR-T-клетки и метаболическое программирование: обзор литературыCAR T cells and metabolic programming: A reviewХатамиШекуфеHatamiShekoufeh

Отдел биохимии

Фаза

Department of Biochemistry

Fasa

shekofeh554@gmail.comКаземиФатемехKazemiFatemeh

Казвин

Qazvin

f.kazemi810@gmail.comДорудгарПарисаDoroudgarParisa

Тегеран

Tehran

parisa.doroudgar@yahoo.comШомейль ШуштариСахарShomeil ShushtariSahar

PhD, отдел аудиологии

Ахваз

PhD, Department of Audiology

Ahvaz

sshomeil@gmail.comАташарМохамад РезаAtashzarMohammad Reza

PhD, отдел иммунологии

Фаза

PhD, Department of Immunology

Fasa

mr.atashzar@yahoo.comУниверситет медицинских наук ФазаИранFasa University of Medical SciencesIslamic Republic of IranЦентр изучения метаболических заболеваний, Институт профилактики некоммуникабельных болезней, Университет медицинских наук КазвинИранMetabolic Disease Research Center, Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical ScienceIslamic Republic of IranСтоматологическая школа, Тегеранский уинверситет медицинских наукИранDental School, Tehran University of Medical SciencesIslamic Republic of IranШкола реабилтитации, Университет медицинских наук Ахваз-УндишапурIslamic Republic of IranSchool of Rehabilitation, Ahvaz Jundishapur University of Medical ScienceIslamic Republic of Iran202507072025274723738Copyright © Хатами Ш., Каземи Ф., Дорудгар П., Шомейль Шуштари С., Аташар М., 20252025Хатами Ш., Каземи Ф., Дорудгар П., Шомейль Шуштари С., Аташар М.Hatami S., Kazemi F., Doroudgar P., Shomeil Shushtari S., Atashzar M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/3155

Терапия с применением Т-лимфоцитов с химерным антигенным рецептором (CAR-Тклетки) стала перспективным методом лечения онкогематологических заболеваний. Хотя она является успешной при системных злокачественных заболеваниях, остаются нерешенными крупные проблемы, которые надо решать для ее более широкого использования. Чтобы преодолеть эти препятствия, следует учитывать метаболические изменения, возникающие при изготовлении CAR-T-клеток, что влияет на их терапевтическую эффективность и специфичность. Поэтому продукция CAR-T-клеток с манипуляцией их метаболических путей могла бы существенно повысить их противоопухолевый иммунный ответ. В настоящем обзоре мы обобщаем последние достижения и новые стратегии, разработанные для улучшения метаболического соответствия и противоопухолевой активности CAR-T-клеточных продуктов.

Chimeric antigen receptor (CAR) T cell therapy shown a promising treatment for haematological malignancies. Although it has successful achievement in hematological malignancies, there are major challenges that remain to be resolved to the broad application. To overcome these obstacles, changes in metabolism during the preparation of CAR T cells increase their therapeutic specificity and potency. Therefore, generation of CAR T cells with manipulated metabolic pathways could beneficially enhance antitumor immunity. Here in this review we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and antitumor activity of CAR T cells products.

ракCAR-T-клеткиметаболизм T-лимфоцитовметаболическое репрограммированиеcancerChimeric Antigen Receptor T cellsT cell metabolismmetabolic reprogrammingReferencesAkbari B., Ghahri-Saremi N., Soltantoyeh T., Hadjati J., Ghassemi S., Mirzaei H.R. Epigenetic strategies to boost CAR T cell therapy. Mol. Ther., 2021, Vol. 29, no. 9, pp. 2640-2659.Akbari B., Ghahri-Saremi N., Soltantoyeh T., Hadjati J., Ghassemi S., Mirzaei H.R. Epigenetic strategies to boost CAR T cell therapy. Mol. Ther., 2021, Vol. 29, no. 9, pp. 2640-2659.Aksoylar H.-I., Tijaro-Ovalle N.M., Boussiotis V.A., Patsoukis N. T cell metabolism in cancer immunotherapy. Immunometabolism, 2020, Vol. 2, no. 3, e200020. doi: 10.20900/immunometab20200020.Aksoylar H.-I., Tijaro-Ovalle N.M., Boussiotis V.A., Patsoukis N. T cell metabolism in cancer immunotherapy. Immunometabolism, 2020, Vol. 2, no. 3, e200020. doi: 10.20900/immunometab20200020.Alizadeh D., Wong R.A., Yang X., Wang D., Pecoraro J.R., Kuo C.-F., Aguilar B., Qi Y., Ann D.K., Starr R., Urak R., Wang X., Forman S.J., Brown C.E. aIL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotypesuperior antitumor activity of CAR-T cells cultured in IL15. Cancer Immunol. Res., 2019, Vol. 7, no. 5, pp. 759-772.Alizadeh D., Wong R.A., Yang X., Wang D., Pecoraro J.R., Kuo C.-F., Aguilar B., Qi Y., Ann D.K., Starr R., Urak R., Wang X., Forman S.J., Brown C.E. aIL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotypesuperior antitumor activity of CAR-T cells cultured in IL15. Cancer Immunol. Res., 2019, Vol. 7, no. 5, pp. 759-772.Alsina M., Shah N., Raje N.S., Jagannath S., Madduri D., Kaufman J.L., Siegel D.S., Munshi N.C., Rosenblatt J., Lin Y., Jakubowiak A., Jasielec J., Timm A., Turka A., Mao P., Martin N., Campbell T.B., Hege K., Bitter H., Petrocca F., Berdeja J.G. Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes. Blood, 2020, Vol. 136, pp. 25-26.Alsina M., Shah N., Raje N.S., Jagannath S., Madduri D., Kaufman J.L., Siegel D.S., Munshi N.C., Rosenblatt J., Lin Y., Jakubowiak A., Jasielec J., Timm A., Turka A., Mao P., Martin N., Campbell T.B., Hege K., Bitter H., Petrocca F., Berdeja J.G. Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes. Blood, 2020, Vol. 136, pp. 25-26.Arcangeli S., Bove C., Mezzanotte C., Camisa B., Falcone L., Manfredi F., Bezzecchi E., Khoury R-E., Norata R., Sanvito F., Ponzoni M., Greco B., Moresco M.-A., Carrabba M.-G., Ciceri F., Bonini C., Bondanza A., Casucci M. CAR T-cell manufacturing from naive/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J. Clin. Invest., 2022, Vol. 132, no. 12, e150807. doi: 10.1172/JCI150807.Arcangeli S., Bove C., Mezzanotte C., Camisa B., Falcone L., Manfredi F., Bezzecchi E., Khoury R-E., Norata R., Sanvito F., Ponzoni M., Greco B., Moresco M.-A., Carrabba M.-G., Ciceri F., Bonini C., Bondanza A., Casucci M. CAR T-cell manufacturing from naive/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J. Clin. Invest., 2022, Vol. 132, no. 12, e150807. doi: 10.1172/JCI150807.Atkins R.M., Menges M.A., Bauer A., Turner J.G., Locke F.L. Metabolically flexible CAR T Cells (mfCAR-T), with constitutive expression of PGC-1α resistant to post translational modifications, exhibit superior survival and function in vitro. Blood, 2020, Vol. 136, p. 30.Atkins R.M., Menges M.A., Bauer A., Turner J.G., Locke F.L. Metabolically flexible CAR T Cells (mfCAR-T), with constitutive expression of PGC-1α resistant to post translational modifications, exhibit superior survival and function in vitro. Blood, 2020, Vol. 136, p. 30.Baixauli F, Martín-Cófreces N.B., Morlino G., Carrasco Y.R., Calabia-Linares C., Veiga E., Serrador J-M., Sánchez-Madrid F. The mitochondrial fission factor dynamin-related protein 1 modulates T-cell receptor signalling at the immune synapse. EMBO J., 2011, Vol. 30, no. 7, pp. 1238-1250.Baixauli F, Martín-Cófreces N.B., Morlino G., Carrasco Y.R., Calabia-Linares C., Veiga E., Serrador J-M., Sánchez-Madrid F. The mitochondrial fission factor dynamin-related protein 1 modulates T-cell receptor signalling at the immune synapse. EMBO J., 2011, Vol. 30, no. 7, pp. 1238-1250.Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.-J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006, Vol. 439, no. 7077, pp. 682-687.Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.-J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006, Vol. 439, no. 7077, pp. 682-687.Battram A., Bachiller M., Urbano-Ispizua Á., Martin-Antonio B. 104 BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7. BMJ, 2020, Vol. 8, pp. A115-A115.Battram A., Bachiller M., Urbano-Ispizua Á., Martin-Antonio B. 104 BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7. BMJ, 2020, Vol. 8, pp. A115-A115.Beavis P.A., Henderson M.A., Giuffrida L., Mills J.K., Sek K., Cross R.S., Davenport A.-J., John L.-B., Mardiana S., Slaney C.-Y., Ricky W., Johnstone R.-W., Trapani J.-A., Stagg J., Loi S., Kats L., Gyorki D., Kershaw M.H., Darcy P.-K. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Invest., 2017, Vol. 127, no. 3, pp. 929-941.Beavis P.A., Henderson M.A., Giuffrida L., Mills J.K., Sek K., Cross R.S., Davenport A.-J., John L.-B., Mardiana S., Slaney C.-Y., Ricky W., Johnstone R.-W., Trapani J.-A., Stagg J., Loi S., Kats L., Gyorki D., Kershaw M.H., Darcy P.-K. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Invest., 2017, Vol. 127, no. 3, pp. 929-941.Beavis P.A., Milenkovski N., Henderson M.A., John L.B., Allard B., Loi S., Kershaw M.-H., Stagg J., Darcy P.-c K. Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res., 2015, Vol. 3, no. 5, pp. 506-517.Beavis P.A., Milenkovski N., Henderson M.A., John L.B., Allard B., Loi S., Kershaw M.-H., Stagg J., Darcy P.-c K. Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res., 2015, Vol. 3, no. 5, pp. 506-517.Beavis P.A., Slaney C.Y., Kershaw M.H., Gyorki D., Neeson P.J., Darcy P.K. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin. Immunol., 2016, Vol. 28, no. 1, pp. 64-72.Beavis P.A., Slaney C.Y., Kershaw M.H., Gyorki D., Neeson P.J., Darcy P.K. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin. Immunol., 2016, Vol. 28, no. 1, pp. 64-72.Bishop E.L., Gudgeon N., Dimeloe S. Control of T cell metabolism by cytokines and hormones. Front. Immunol., 2021, Vol. 12, 653605. doi: 10.3389/fimmu.2021.653605.Bishop E.L., Gudgeon N., Dimeloe S. Control of T cell metabolism by cytokines and hormones. Front. Immunol., 2021, Vol. 12, 653605. doi: 10.3389/fimmu.2021.653605.Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.-R., Freeman G.-J., Vignali D.-A., Wherry E.-J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol., 2009, Vol. 10, no. 1, pp. 29-37.Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.-R., Freeman G.-J., Vignali D.-A., Wherry E.-J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol., 2009, Vol. 10, no. 1, pp. 29-37.Bonini C., Mondino A. Adoptive T-cell therapy for cancer: The era of engineered T cells. Eur. J. Immunol., 2015, Vol. 45, no. 9, pp. 2457-2469.Bonini C., Mondino A. Adoptive T-cell therapy for cancer: The era of engineered T cells. Eur. J. Immunol., 2015, Vol. 45, no. 9, pp. 2457-2469.Bose S., Le A. Glucose metabolism in cancer. Adv. Exp. Med. Biol., 2018, Vol. 1063, pp. 3-12.Bose S., Le A. Glucose metabolism in cancer. Adv. Exp. Med. Biol., 2018, Vol. 1063, pp. 3-12.Buck M.D., O’Sullivan D., Geltink R.I.K., Curtis J.D., Chang C.-H., Sanin D.E., Qiu J., Kretz O., Braas D., Windt G.-W., Chen Q., Huang S.-C.-C., O’Neill C.-M., Edelson B.-T., Pearce E.-J., Sesaki H., Huber T.-B., Rambold A.-S., Pearce E.-J. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell, 2016, Vol. 166, no. 1, pp. 63-76.Buck M.D., O’Sullivan D., Geltink R.I.K., Curtis J.D., Chang C.-H., Sanin D.E., Qiu J., Kretz O., Braas D., Windt G.-W., Chen Q., Huang S.-C.-C., O’Neill C.-M., Edelson B.-T., Pearce E.-J., Sesaki H., Huber T.-B., Rambold A.-S., Pearce E.-J. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell, 2016, Vol. 166, no. 1, pp. 63-76.Cao Y., Lu W., Sun R., Jin X., Cheng L., He X., Wang L., Yuan T., Lyu C., Zhao M. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell nonHodgkin lymphoma. Front. Oncol., 2019, Vol. 9, 767. doi: 10.3389/fonc.2019.00767.Cao Y., Lu W., Sun R., Jin X., Cheng L., He X., Wang L., Yuan T., Lyu C., Zhao M. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell nonHodgkin lymphoma. Front. Oncol., 2019, Vol. 9, 767. doi: 10.3389/fonc.2019.00767.Carrio R., Bathe O.F., Malek T.R. Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7-and IL-15-rich environment. J. Immunol., 2004, Vol. 172, no. 12, pp. 7315-7323.Carrio R., Bathe O.F., Malek T.R. Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7-and IL-15-rich environment. J. Immunol., 2004, Vol. 172, no. 12, pp. 7315-7323.Catalán E., Charni S., Jaime P., Aguiló J.I., Enríquez J.A., Naval J., Julián P., Martín V., Alberto A. MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. Oncoimmunology, 2015, Vol. 4, no. 1, e985924. doi: 10.4161/2162402X.2014.985924.Catalán E., Charni S., Jaime P., Aguiló J.I., Enríquez J.A., Naval J., Julián P., Martín V., Alberto A. MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. Oncoimmunology, 2015, Vol. 4, no. 1, e985924. doi: 10.4161/2162402X.2014.985924.Chamoto K., Chowdhury P.S., Kumar A., Sonomura K., Matsuda F., Fagarasan S., Honjo T. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl. Acad. Sci. USA, 2017, Vol. 114, no. 5, pp. E761-E70.Chamoto K., Chowdhury P.S., Kumar A., Sonomura K., Matsuda F., Fagarasan S., Honjo T. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl. Acad. Sci. USA, 2017, Vol. 114, no. 5, pp. E761-E70.Chang C.-H., Curtis J.D., Maggi L.B. Jr., Faubert B., Villarino A.V., O’Sullivan D., Huang S.-C.-C., Windt G.-J.W., Blagih J., Qiu J., Weber J.-D., Pearce E.-J., Jones R-G., Pearce E-L. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell, 2013, Vol. 153, no. 6, pp. 1239-1251.Chang C.-H., Curtis J.D., Maggi L.B. Jr., Faubert B., Villarino A.V., O’Sullivan D., Huang S.-C.-C., Windt G.-J.W., Blagih J., Qiu J., Weber J.-D., Pearce E.-J., Jones R-G., Pearce E-L. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell, 2013, Vol. 153, no. 6, pp. 1239-1251.Chang C.-H., Qiu J., O’Sullivan D., Buck M.D., Noguchi T., Curtis J.D., Chen Q., Gindin M., Gubin M.-c M., van der Windt G.-J.W., Tonc E., Schreiber R.-D., Pearce E.-J., Pearce E.-L. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, Vol. 162, no. 6, pp. 1229-1241.Chang C.-H., Qiu J., O’Sullivan D., Buck M.D., Noguchi T., Curtis J.D., Chen Q., Gindin M., Gubin M.-c M., van der Windt G.-J.W., Tonc E., Schreiber R.-D., Pearce E.-J., Pearce E.-L. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, Vol. 162, no. 6, pp. 1229-1241.Chatterjee S., Chakraborty P., Daenthanasanmak A., Iamsawat S., Andrejeva G., Luevano L.A., Wolf M., Baliga U., Krieg C., Beeson C.-C., Mehrotra M., Hill E.-G., Rathmell J.-C., Yu X.-Z., Kraft A-S., Mehrotra S. Targeting PIM Kinase with PD1 Inhibition improves immunotherapeutic antitumor T-cell responsePIM-K inhibition potentiates ACT. Clin. Cancer Res., 2019, Vol. 25, no. 3, pp. 1036-1049.Chatterjee S., Chakraborty P., Daenthanasanmak A., Iamsawat S., Andrejeva G., Luevano L.A., Wolf M., Baliga U., Krieg C., Beeson C.-C., Mehrotra M., Hill E.-G., Rathmell J.-C., Yu X.-Z., Kraft A-S., Mehrotra S. Targeting PIM Kinase with PD1 Inhibition improves immunotherapeutic antitumor T-cell responsePIM-K inhibition potentiates ACT. Clin. Cancer Res., 2019, Vol. 25, no. 3, pp. 1036-1049.Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol., 2013, Vol. 13, no. 4, pp. 227-242.Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol., 2013, Vol. 13, no. 4, pp. 227-242.Corrado M., Pearce E.L. Targeting memory T cell metabolism to improve immunity. J. Clin. Invest., 2022, Vol. 132, no. 1, e148546. doi: 10.1172/JCI148546.Corrado M., Pearce E.L. Targeting memory T cell metabolism to improve immunity. J. Clin. Invest., 2022, Vol. 132, no. 1, e148546. doi: 10.1172/JCI148546.Crawford A., Wherry E.J. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr. Opin. Immunol., 2009, Vol. 21, no. 2, pp. 179-186.Crawford A., Wherry E.J. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr. Opin. Immunol., 2009, Vol. 21, no. 2, pp. 179-186.Cronin S.J., Seehus C., Weidinger A., Talbot S., Reissig S., Seifert M., Pierson Y., McNeill E., Longhi M. S., Turnes B.-L., Kreslavsky T., Kogler M., Hoffmann D., Ticevic M., Scheffer D.-L., Tortola L., Cikes D., Jais A., Rangachari M., Rao S., Paolino M., Novatchkova M., Aichinger M., Barrett L., Latremoliere A., Wirnsberger G., Lametschwandtner G., Busslinger M., Zicha S., Latini A., Robson S.-C., Waisman A., Andrews N., Costigan M., Channon K.-M., Weiss G., Kozlov A.-V., Tebbe M., Johnsson K., Woolf C-J., Penninger J-M. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature, 2018, Vol. 563, no. 7732, pp. 564-568.Cronin S.J., Seehus C., Weidinger A., Talbot S., Reissig S., Seifert M., Pierson Y., McNeill E., Longhi M. S., Turnes B.-L., Kreslavsky T., Kogler M., Hoffmann D., Ticevic M., Scheffer D.-L., Tortola L., Cikes D., Jais A., Rangachari M., Rao S., Paolino M., Novatchkova M., Aichinger M., Barrett L., Latremoliere A., Wirnsberger G., Lametschwandtner G., Busslinger M., Zicha S., Latini A., Robson S.-C., Waisman A., Andrews N., Costigan M., Channon K.-M., Weiss G., Kozlov A.-V., Tebbe M., Johnsson K., Woolf C-J., Penninger J-M. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature, 2018, Vol. 563, no. 7732, pp. 564-568.Cui G., Staron M.M., Gray S.M., Ho P.-C., Amezquita R.A., Wu J., Kaech S.-M. IL-7-induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity. Cell, 2015, Vol. 161, no. 4, pp. 750-761.Cui G., Staron M.M., Gray S.M., Ho P.-C., Amezquita R.A., Wu J., Kaech S.-M. IL-7-induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity. Cell, 2015, Vol. 161, no. 4, pp. 750-761.Curran K.J., Pegram H.J., Brentjens R.J. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J. Gene Med., 2012, Vol. 14, no. 6, pp. 405-415.Curran K.J., Pegram H.J., Brentjens R.J. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J. Gene Med., 2012, Vol. 14, no. 6, pp. 405-415.Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb. Exp. Pharmacol., 2008, Vol. 181, pp. 329-342.Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb. Exp. Pharmacol., 2008, Vol. 181, pp. 329-342.Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 1993, Vol. 90, no. 2, pp. 720-724.Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 1993, Vol. 90, no. 2, pp. 720-724.Foskolou I.P., Barbieri L., Vernet A., Bargiela D., Cunha P.P., Velica P., Suh E., Pietsch S., Matuleviciute R., Rundqvist H., McIntyre D., Smith K.-G.C., Johnson R.-S. The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome. Blood Adv., 2020, Vol. 4, no. 18, pp. 4483-4493.Foskolou I.P., Barbieri L., Vernet A., Bargiela D., Cunha P.P., Velica P., Suh E., Pietsch S., Matuleviciute R., Rundqvist H., McIntyre D., Smith K.-G.C., Johnson R.-S. The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome. Blood Adv., 2020, Vol. 4, no. 18, pp. 4483-4493.Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., Kirkwood J.-M., Olive D., Kuchroo V., Zarour H.-M. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1tumor antigen-specific T cells coexpress BTLA and PD-1. Cancer Res., 2012, Vol. 72, no. 4, pp. 887-896.Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., Kirkwood J.-M., Olive D., Kuchroo V., Zarour H.-M. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1tumor antigen-specific T cells coexpress BTLA and PD-1. Cancer Res., 2012, Vol. 72, no. 4, pp. 887-896.Fraietta J.A., Nobles C.L., Sammons M.A., Lundh S., Carty S.A., Reich T.J., Cogdill A.-P., Morrissette J.J.-D., de Nizio J.-E., Reddy S., Hwang Y., Gohil M., Kulikovskaya I., Nazimuddin F., Gupta M., Chen F., Everett J.-K., Alexander K.-A., Lin-Shiao E., Gee M.-H., Liu X., Young R.-M., Ambrose D., Wang Y., Xu J., Jordan M.-S., Marcucci K.-T., Levine L.B., Garcia K.-C., Zhao Y., Kalos M., Porter D.-L., Kohli R.-M., Lacey S.-F., Berger S.-L., Bushman F.-D., June C.-H., Melenhorst J.J. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, Vol. 558, no. 7709, pp. 307-312.Fraietta J.A., Nobles C.L., Sammons M.A., Lundh S., Carty S.A., Reich T.J., Cogdill A.-P., Morrissette J.J.-D., de Nizio J.-E., Reddy S., Hwang Y., Gohil M., Kulikovskaya I., Nazimuddin F., Gupta M., Chen F., Everett J.-K., Alexander K.-A., Lin-Shiao E., Gee M.-H., Liu X., Young R.-M., Ambrose D., Wang Y., Xu J., Jordan M.-S., Marcucci K.-T., Levine L.B., Garcia K.-C., Zhao Y., Kalos M., Porter D.-L., Kohli R.-M., Lacey S.-F., Berger S.-L., Bushman F.-D., June C.-H., Melenhorst J.J. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, Vol. 558, no. 7709, pp. 307-312.Frauwirth K.A., Riley J.L., Harris M.H., Parry R.V., Rathmell J.C., Plas D.R., Elstrom R.-L., June C.-H., Thompson C.-B. The CD28 signaling pathway regulates glucose metabolism. Immunity, 2002, Vol. 16, no. 6, pp. 769-777.Frauwirth K.A., Riley J.L., Harris M.H., Parry R.V., Rathmell J.C., Plas D.R., Elstrom R.-L., June C.-H., Thompson C.-B. The CD28 signaling pathway regulates glucose metabolism. Immunity, 2002, Vol. 16, no. 6, pp. 769-777.Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., Jain R.K. Hypoxia and acidosis independently upregulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res., 2001, Vol. 61, no. 16, pp. 6020-6024.Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., Jain R.K. Hypoxia and acidosis independently upregulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res., 2001, Vol. 61, no. 16, pp. 6020-6024.Fultang L., Booth S., Yogev O., Martins da Costa B., Tubb V., Panetti S., Stavrou V., Scarpa U., Jankevics A., Lloyd G., Southam A., Lee S.-P., Dunn W.-B., Chesler L., Mussai F., de Santo C. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood, 2020, Vol. 136, no. 10, pp. 1155-1160.Fultang L., Booth S., Yogev O., Martins da Costa B., Tubb V., Panetti S., Stavrou V., Scarpa U., Jankevics A., Lloyd G., Southam A., Lee S.-P., Dunn W.-B., Chesler L., Mussai F., de Santo C. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood, 2020, Vol. 136, no. 10, pp. 1155-1160.Geiger R., Rieckmann J.C., Wolf T., Basso C., Feng Y., Fuhrer T., Kogadeeva M., Picotti P., Meissner F., Mann M., Zamboni N., Sallusto F., Lanzavecchia A. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell, 2016, Vol. 167, no. 3, pp. 829-842.e13.Geiger R., Rieckmann J.C., Wolf T., Basso C., Feng Y., Fuhrer T., Kogadeeva M., Picotti P., Meissner F., Mann M., Zamboni N., Sallusto F., Lanzavecchia A. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell, 2016, Vol. 167, no. 3, pp. 829-842.e13.Ghassemi S., Martinez-Becerra F.J., Master A.M., Richman S.A., Heo D., Leferovich J., Tu Y., García-Cañaveras J.-C., Ayari A., Lu Y., Wang A., Rabinowitz J.-D., Milone M-C., June C.-H., O’Connor R.-S. Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design. Mol. Ther. Methods Clin. Dev., 2020, Vol. 18, pp. 595-606.Ghassemi S., Martinez-Becerra F.J., Master A.M., Richman S.A., Heo D., Leferovich J., Tu Y., GarcíaCañaveras J.-C., Ayari A., Lu Y., Wang A., Rabinowitz J.-D., Milone M-C., June C.-H., O’Connor R.-S. Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design. Mol. Ther. Methods Clin. Dev., 2020, Vol. 18, pp. 595-606.Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA, 1989, Vol. 86, no. 24, pp. 10024-10028.Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA, 1989, Vol. 86, no. 24, pp. 10024-10028.Haji-Fatahaliha M., Hosseini M., Akbarian A., Sadreddini S., Jadidi-Niaragh F., Yousefi M. CAR-modified T-cell therapy for cancer: an updated review. Artif. Cells Nanomed. Biotechnol., 2016, Vol. 44, no. 6, pp. 1339-1349.Haji-Fatahaliha M., Hosseini M., Akbarian A., Sadreddini S., Jadidi-Niaragh F., Yousefi M. CAR-modified T-cell therapy for cancer: an updated review. Artif. Cells Nanomed. Biotechnol., 2016, Vol. 44, no. 6, pp. 1339-1349.Hermans D., Gautam S., García-Cañaveras J.C., Gromer D., Mitra S., Spolski R., Li P., Christensen S., Nguyen R., Lin J.-X., Oh J., Du N., Veenbergen S., Fioravanti J., Ebina-Shibuya R., Bleck C., Neckers L.-M., Rabinowitz J.-D., Gattinoni L., Leonard W.-J. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. Proc. Natl. Acad. Sci. USA, 2020, Vol. 117, no. 11, pp. 6047-6055.Hermans D., Gautam S., García-Cañaveras J.C., Gromer D., Mitra S., Spolski R., Li P., Christensen S., Nguyen R., Lin J.-X., Oh J., Du N., Veenbergen S., Fioravanti J., Ebina-Shibuya R., Bleck C., Neckers L.-M., Rabinowitz J.-D., Gattinoni L., Leonard W.-J. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. Proc. Natl. Acad. Sci. USA, 2020, Vol. 117, no. 11, pp. 6047-6055.Hillerdal V., Essand M. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs, 2015, Vol. 29, no. 2, pp. 75-89.Hillerdal V., Essand M. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs, 2015, Vol. 29, no. 2, pp. 75-89.Hirabayashi K., Du H., Xu Y., Shou P., Zhou X., Fucá G., Landoni E., Sun C., Chen Y., Savoldo B., Dotti G. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer, 2021, Vol. 2, no. 9, pp. 904-918.Hirabayashi K., Du H., Xu Y., Shou P., Zhou X., Fucá G., Landoni E., Sun C., Chen Y., Savoldo B., Dotti G. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer, 2021, Vol. 2, no. 9, pp. 904-918.Ho P.-C., Bihuniak J.D., Macintyre A.N., Staron M., Liu X., Amezquita R., Tsui Y.-C., Cui G., Micevic G., Perales J.-C., Kleinstein S.-H., Abel E.-D., Insogna K.-L., Feske S., Locasale J.-W., Bosenberg M.-W., Rathmell J.-C., Kaech S.-M. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell, 2015, Vol. 162, no. 6, pp. 1217-1228.Ho P.-C., Bihuniak J.D., Macintyre A.N., Staron M., Liu X., Amezquita R., Tsui Y.-C., Cui G., Micevic G., Perales J.-C., Kleinstein S.-H., Abel E.-D., Insogna K.-L., Feske S., Locasale J.-W., Bosenberg M.-W., Rathmell J.-C., Kaech S.-M. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell, 2015, Vol. 162, no. 6, pp. 1217-1228.Ho P.-C., Liu P.-S. Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. J. Immunother. Cancer, 2016, Vol. 4, no. 1, pp. 1-9.Ho P.-C., Liu P.-S. Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. J. Immunother. Cancer, 2016, Vol. 4, no. 1, pp. 1-9.Huang Q., Xia J., Wang L., Wang X., Ma X., Deng Q., Lu Y., Kumar M., Zhou Z., Li L., Zeng Z., Young K.-H., Yi Q., Zhang M., Li Y. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J. Hematol. Oncol., 2018, Vol. 11, no. 1, pp. 1-12.Huang Q., Xia J., Wang L., Wang X., Ma X., Deng Q., Lu Y., Kumar M., Zhou Z., Li L., Zeng Z., Young K.-H., Yi Q., Zhang M., Li Y. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J. Hematol. Oncol., 2018, Vol. 11, no. 1, pp. 1-12.Huang Y., Li D., Qin D., Gou H., Wei W., Wang Y., Wei Y.-Q., Wang W. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy. Gene Ther., 2018, Vol. 25, no. 3, pp. 192-197.Huang Y., Li D., Qin D., Gou H., Wei W., Wang Y., Wei Y.-Q., Wang W. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy. Gene Ther., 2018, Vol. 25, no. 3, pp. 192-197.Jacobs S.R., Herman C.E., MacIver N.J., Wofford J.A., Wieman H.L., Hammen J.J., Rathmell J.-C. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol., 2008, Vol. 180, no. 7, pp. 4476-4486.Jacobs S.R., Herman C.E., MacIver N.J., Wofford J.A., Wieman H.L., Hammen J.J., Rathmell J.-C. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol., 2008, Vol. 180, no. 7, pp. 4476-4486.Jena B., Rushworth D., McNamara G.T., Cooper L.J. Mitochondrial biomass as a measure of fitness for T cells expressing chimeric antigen receptors. Blood, 2015, Vol. 126, no. 23, p. 3242.Jena B., Rushworth D., McNamara G.T., Cooper L.J. Mitochondrial biomass as a measure of fitness for T cells expressing chimeric antigen receptors. Blood, 2015, Vol. 126, no. 23, p. 3242.Jiang B. Aerobic glycolysis and high level of lactate in cancer metabolism and microenvironment. Genes Dis., 2017, Vol. 4, no. 1, pp. 25-27.Jiang B. Aerobic glycolysis and high level of lactate in cancer metabolism and microenvironment. Genes Dis., 2017, Vol. 4, no. 1, pp. 25-27.Jiang J., Srivastava S., Zhang J. Starve cancer cells of glutamine: break the spell or make a hungry monster? Cancers, 2019, Vol. 11, no. 6, 804. doi: 10.3390/cancers11060804.Jiang J., Srivastava S., Zhang J. Starve cancer cells of glutamine: break the spell or make a hungry monster? Cancers, 2019, Vol. 11, no. 6, 804. doi: 10.3390/cancers11060804.Jin H.-T., Anderson A.C., Tan W.G., West E.E., Ha S.-J., Araki K., Freeman G.-J., Kuchroo V.-K., Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA, 2010, Vol. 107, no. 33, pp. 14733-14738.Jin H.-T., Anderson A.C., Tan W.G., West E.E., Ha S.-J., Araki K., Freeman G.-J., Kuchroo V.-K., Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA, 2010, Vol. 107, no. 33, pp. 14733-14738.John L.B., Kershaw M.H., Darcy P.K. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology, 2013, Vol. 2, no. 10, e26286. doi: 10.4161/onci.26286.John L.B., Kershaw M.H., Darcy P.K. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology, 2013, Vol. 2, no. 10, e26286. doi: 10.4161/onci.26286.Joller N., Hafler J.P., Brynedal B., Kassam N., Spoer S., Levin S.D., Sharpe A.-H., Kuchroo V.-K. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol., 2011, Vol. 186, no. 3, pp. 1338-1342.Joller N., Hafler J.P., Brynedal B., Kassam N., Spoer S., Levin S.D., Sharpe A.-H., Kuchroo V.-K. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol., 2011, Vol. 186, no. 3, pp. 1338-1342.Jones N., Vincent E.E., Cronin J.G., Panetti S., Chambers M., Holm S.R., Sian E., Owens S.-E., Francis N.-J., Finlay D.-K., Thornton C.-A. Akt and STAT5 mediate naïve human CD4+ T-cell early metabolic response to TCR stimulation. Nat. Commun., 2019, Vol. 10, no. 1, pp. 1-13.Jones N., Vincent E.E., Cronin J.G., Panetti S., Chambers M., Holm S.R., Sian E., Owens S.-E., Francis N.-J., Finlay D.-K., Thornton C.-A. Akt and STAT5 mediate naïve human CD4+ T-cell early metabolic response to TCR stimulation. Nat. Commun., 2019, Vol. 10, no. 1, pp. 1-13.Jung I.-Y., Kim Y.-Y., Yu H.-S., Lee M., Kim S., Lee J. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res., 2018, Vol. 78, no. 16, pp. 4692-4703.Jung I.-Y., Kim Y.-Y., Yu H.-S., Lee M., Kim S., Lee J. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res., 2018, Vol. 78, no. 16, pp. 4692-4703.Kagoya Y., Nakatsugawa M., Yamashita Y., Ochi T., Guo T., Anczurowski M., Saso K., Butler M.-O., Arrowsmith C.-H., Hirano N. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest., 2016, Vol. 126, no. 9, pp. 3479-3494.Kagoya Y., Nakatsugawa M., Yamashita Y., Ochi T., Guo T., Anczurowski M., Saso K., Butler M.-O., Arrowsmith C.-H., Hirano N. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest., 2016, Vol. 126, no. 9, pp. 3479-3494.Kawalekar O.U., O’Connor R.S., Fraietta J.A., Guo L., McGettigan S.E., Posey A.D. Jr., Patel P.-R., Guedan S., Scholler J., Keith B., Snyder N.-W., Blair I.-A., Milone M.-C., June C.-H. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity, 2016, Vol. 44, no. 2, pp. 380-390.Kawalekar O.U., O’Connor R.S., Fraietta J.A., Guo L., McGettigan S.E., Posey A.D. Jr., Patel P.-R., Guedan S., Scholler J., Keith B., Snyder N.-W., Blair I.-A., Milone M.-C., June C.-H. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity, 2016, Vol. 44, no. 2, pp. 380-390.Kim E.H., Sullivan J.A., Plisch E.H., Tejera M.M., Jatzek A., Choi K.Y., Suresh M. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J. Immunol., 2012, Vol. 188, no. 9, pp. 4305-4314.Kim E.H., Sullivan J.A., Plisch E.H., Tejera M.M., Jatzek A., Choi K.Y., Suresh M. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J. Immunol., 2012, Vol. 188, no. 9, pp. 4305-4314.Klebanoff C.A., Crompton J.G., Leonardi A.J., Yamamoto T.N., Chandran S.S., Eil R.L., Sukumar M., Vodnala S.-K., Hu J., Ji Y., Clever D., Black M.-A., Gurusamy D., Kruhlak M.-J., Jin P., Stroncek D.-F., Gattinoni L., Feldman S.-A., Restifo N.-P. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptorengineered adoptive immunotherapy. JCI insight, 2017, Vol. 2, no. 23, e95103. doi: 10.1172/jci.insight.95103.Klebanoff C.A., Crompton J.G., Leonardi A.J., Yamamoto T.N., Chandran S.S., Eil R.L., Sukumar M., Vodnala S.-K., Hu J., Ji Y., Clever D., Black M.-A., Gurusamy D., Kruhlak M.-J., Jin P., Stroncek D.-F., Gattinoni L., Feldman S.-A., Restifo N.-P. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptorengineered adoptive immunotherapy. JCI insight, 2017, Vol. 2, no. 23, e95103. doi: 10.1172/jci.insight.95103.Kondo T., Ando M., Nagai N., Tomisato W., Srirat T., Liu B., Mise-Omata S., Ikeda M., Chikuma S., Nishimasu H., Nureki O., Ohmura M., Hayakawa N., Hishiki T., Uchibori R., Ozawa K., Yoshimura A. The NOTCH– FOXM1 axis plays a key role in mitochondrial biogenesis in the induction of human stem cell memory-like CAR-T cells. Cancer Res., 2020, Vol. 80, no. 3, pp. 471-483.Kondo T., Ando M., Nagai N., Tomisato W., Srirat T., Liu B., Mise-Omata S., Ikeda M., Chikuma S., Nishimasu H., Nureki O., Ohmura M., Hayakawa N., Hishiki T., Uchibori R., Ozawa K., Yoshimura A. The NOTCH– FOXM1 axis plays a key role in mitochondrial biogenesis in the induction of human stem cell memory-like CAR-T cells. Cancer Res., 2020, Vol. 80, no. 3, pp. 471-483.Kouidhi S., Ben Ayed F., Benammar Elgaaied A. Targeting tumor metabolism: a new challenge to improve immunotherapy. Front. Immunol., 2018, Vol. 9, 353. doi: 10.3389/fimmu.2018.00353.Kouidhi S., Ben Ayed F., Benammar Elgaaied A. Targeting tumor metabolism: a new challenge to improve immunotherapy. Front. Immunol., 2018, Vol. 9, 353. doi: 10.3389/fimmu.2018.00353.Leone R.D., Zhao L., Englert J.M., Sun I.-M., Oh M.-H., Sun I.-H., Arwood M.-L., Bettencourt I.-A., Patel C.-H., Wen J., Tam A., Blosser R.-L., Prchalova E., Alt J., Rais R., Slusher B.-S., Powell J.-D. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science, 2019, Vol. 366, no. 6468, pp. 1013-1021.Leone R.D., Zhao L., Englert J.M., Sun I.-M., Oh M.-H., Sun I.-H., Arwood M.-L., Bettencourt I.-A., Patel C.-H., Wen J., Tam A., Blosser R.-L., Prchalova E., Alt J., Rais R., Slusher B.-S., Powell J.-D. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science, 2019, Vol. 366, no. 6468, pp. 1013-1021.Li L., Li Q., Yan Z.X., Sheng L.S., Fu D., Xu P., Wang L., Zhao W.-L. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci. Rep., 2022, Vol. 12, no. 1, 12506. doi: 10.1038/s41598-022-16616-2.Li L., Li Q., Yan Z.X., Sheng L.S., Fu D., Xu P., Wang L., Zhao W.-L. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci. Rep., 2022, Vol. 12, no. 1, 12506. doi: 10.1038/s41598-022-16616-2.Lin H., Cheng J., Mu W., Zhou J., Zhu L. Advances in universal CAR-T cell therapy. Front. Immunol., 2021, Vol. 12, 744823. doi: 10.3389/fimmu.2021.744823.Lin H., Cheng J., Mu W., Zhou J., Zhu L. Advances in universal CAR-T cell therapy. Front. Immunol., 2021, Vol. 12, 744823. doi: 10.3389/fimmu.2021.744823.Long A.H., Haso W.M., Shern J.F., Wanhainen K.M., Murgai M., Ingaramo M., Smith J-P., Walker A-J., Kohler M-E., Venkateshwara V-R., Kaplan R-N., Patterson G-H., Fry T-J., Orentas R-J., Mackall C-L. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med., 2015, Vol. 21, no. 6, pp. 581-590.Long A.H., Haso W.M., Shern J.F., Wanhainen K.M., Murgai M., Ingaramo M., Smith J-P., Walker A-J., Kohler M-E., Venkateshwara V-R., Kaplan R-N., Patterson G-H., Fry T-J., Orentas R-J., Mackall C-L. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med., 2015, Vol. 21, no. 6, pp. 581-590.López-Cantillo G., Urueña C., Camacho B.A., Ramírez-Segura C. CAR-T cell performance: how to improve their persistence? Front. Immunol., 2022, Vol. 13, 878209. doi: 10.3389/fimmu.2022.878209.López-Cantillo G., Urueña C., Camacho B.A., Ramírez-Segura C. CAR-T cell performance: how to improve their persistence? Front. Immunol., 2022, Vol. 13, 878209. doi: 10.3389/fimmu.2022.878209.Loschinski R., Böttcher M., Stoll A., Bruns H., Mackensen A., Mougiakakos D. IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner. Oncotarget, 2018, Vol. 9, no. 17, pp. 13125-13138.Loschinski R., Böttcher M., Stoll A., Bruns H., Mackensen A., Mougiakakos D. IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner. Oncotarget, 2018, Vol. 9, no. 17, pp. 13125-13138.Lynn R.C., Weber E.W., Sotillo E., Gennert D., Xu P., Good Z., Anbunathan H., Lattin J., Jones R., Tieu V., Nagaraja S., Granja J., Bourcy C.-F.-A., Majzner R., Satpathy A.-T., Quake S.-R., Monje M., Chang H.-Y., Mackall C.-L. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 2019, Vol. 576, no. 7786, pp. 293-300.Lynn R.C., Weber E.W., Sotillo E., Gennert D., Xu P., Good Z., Anbunathan H., Lattin J., Jones R., Tieu V., Nagaraja S., Granja J., Bourcy C.-F.-A., Majzner R., Satpathy A.-T., Quake S.-R., Monje M., Chang H.-Y., Mackall C.-L. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 2019, Vol. 576, no. 7786, pp. 293-300.Ma X., Bi E., Lu Y., Su P., Huang C., Liu L., Qiang Wang Q., Yang M., Kalady M.-F., Qian J., Zhang A., Gupte A.-A., Hamilton D.-J., Zheng C., Yi Q. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab., 2019, Vol. 30, no. 1, pp. 143-156.e5.Ma X., Bi E., Lu Y., Su P., Huang C., Liu L., Qiang Wang Q., Yang M., Kalady M.-F., Qian J., Zhang A., Gupte A.-A., Hamilton D.-J., Zheng C., Yi Q. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab., 2019, Vol. 30, no. 1, pp. 143-156.e5.Ma X., Shou P., Smith C., Chen Y., Du H., Sun C., Porterfield Kren N., Michaud D., Ahn S., Vincent B., Savoldo B., Pylayeva-Gupta Y., Zhang S., Dotti G., Xu Y. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol., 2020, Vol. 38, no. 4, pp. 448-459.Ma X., Shou P., Smith C., Chen Y., Du H., Sun C., Porterfield Kren N., Michaud D., Ahn S., Vincent B., Savoldo B., Pylayeva-Gupta Y., Zhang S., Dotti G., Xu Y. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol., 2020, Vol. 38, no. 4, pp. 448-459.Majzner R.G., Mackall C.L. Tumor antigen escape from CAR T-cell therapy. Cancer Dscov., 2018, Vol. 8, no. 10, pp. 1219-1226.Majzner R.G., Mackall C.L. Tumor antigen escape from CAR T-cell therapy. Cancer Dscov., 2018, Vol. 8, no. 10, pp. 1219-1226.Man K., Gabriel S.-S., Liao Y., Gloury R., Preston S., Henstridge D.-C., Pellegrini M., Zehn D., BerberichSiebelt F., Febbraio M.-A., Shi W., Kallies A. Transcription factor IRF4 promotes CD8 T cell exhaustion and limits the development of memory-like t cells during chronic infection. Immunity, 2017, Vol. 47, no. 6, pp. 1129-1141.e5.Man K., Gabriel S.-S., Liao Y., Gloury R., Preston S., Henstridge D.-C., Pellegrini M., Zehn D., BerberichSiebelt F., Febbraio M.-A., Shi W., Kallies A. Transcription factor IRF4 promotes CD8 T cell exhaustion and limits the development of memory-like t cells during chronic infection. Immunity, 2017, Vol. 47, no. 6, pp. 1129-1141.e5.Marchesi F., Vignali D., Manini B., Rigamonti A., Monti P. Manipulation of glucose availability to boost cancer immunotherapies. Cancers, 2020, Vol. 12, no. 10, 2940. doi: 10.3390/cancers12102940.Marchesi F., Vignali D., Manini B., Rigamonti A., Monti P. Manipulation of glucose availability to boost cancer immunotherapies. Cancers, 2020, Vol. 12, no. 10, 2940. doi: 10.3390/cancers12102940.Marofi F., Motavalli R., Safonov V.A., Thangavelu L., Yumashev A.V., Alexander M., Shomali N., Chartrand M.-S., Pathak Y., Jarahian M., Izadi S., Hassanzadeh A., Shirafkan N., Tahmasebi S., Motavalli Khiavi F. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res. Ther., 2021, Vol. 12, no. 1, 81. doi: 10.1186/s13287-020-02128-1.Marofi F., Motavalli R., Safonov V.A., Thangavelu L., Yumashev A.V., Alexander M., Shomali N., Chartrand M.-S., Pathak Y., Jarahian M., Izadi S., Hassanzadeh A., Shirafkan N., Tahmasebi S., Motavalli Khiavi F. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res. Ther., 2021, Vol. 12, no. 1, 81. doi: 10.1186/s13287-020-02128-1.Menk A.V., Scharping N.E., Rivadeneira D.B., Calderon M.J., Watson M.J., Dunstane D., Watkins S.-C., Delgoffe G.-M. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J. Exp. Med., 2018, Vol. 215, no. 4, pp. 1091-1100.Menk A.V., Scharping N.E., Rivadeneira D.B., Calderon M.J., Watson M.J., Dunstane D., Watkins S.-C., Delgoffe G.-M. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J. Exp. Med., 2018, Vol. 215, no. 4, pp. 1091-1100.Mousset C.M., Hobo W., de Ligt A., Baardman S., Schaap N.P., Jansen J.H., Waart A.-B.V.-D., Dolstra H. Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer Immunol. Immunother., 2020, Vol. 69, no. 11, pp. 2259-2273.Mousset C.M., Hobo W., de Ligt A., Baardman S., Schaap N.P., Jansen J.H., Waart A.-B.V.-D., Dolstra H. Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer Immunol. Immunother., 2020, Vol. 69, no. 11, pp. 2259-2273.Nabe S., Yamada T., Suzuki J., Toriyama K., Yasuoka T., Kuwahara M., Shiraishi A., Takenaka K., Yasukawa M., Yamashita M. Reinforce the antitumor activity of CD8+ T cells via glutamine restriction. Cancer Sci., 2018, Vol. 109, no. 12, pp. 3737-3750.Nabe S., Yamada T., Suzuki J., Toriyama K., Yasuoka T., Kuwahara M., Shiraishi A., Takenaka K., Yasukawa M., Yamashita M. Reinforce the antitumor activity of CD8+ T cells via glutamine restriction. Cancer Sci., 2018, Vol. 109, no. 12, pp. 3737-3750.Ninomiya S., Narala N., Huye L., Yagyu S., Savoldo B., Dotti G., Heslop H.-E., Brenner M.-K., Rooney C. M., Ramos C.-A. Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood,, 2015, Vol. 125, no. 25, pp. 3905-3916.Ninomiya S., Narala N., Huye L., Yagyu S., Savoldo B., Dotti G., Heslop H.-E., Brenner M.-K., Rooney C. M., Ramos C.-A. Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood,, 2015, Vol. 125, no. 25, pp. 3905-3916.Ohno M., Ohkuri T., Kosaka A., Tanahashi K., June C.H., Natsume A., Okada H. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J. Immunother. Cancer, 2013, Vol. 1, no. 1, pp. 1-12.Ohno M., Ohkuri T., Kosaka A., Tanahashi K., June C.H., Natsume A., Okada H. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J. Immunother. Cancer, 2013, Vol. 1, no. 1, pp. 1-12.Pacella I., Procaccini C., Focaccetti C., Miacci S., Timperi E., Faicchia D., Severa M., Rizzo F., Coccia E.-M., Bonacina F., Mitro N., Norata G.-D., Rossetti G., Ranzani V., Pagani M., Giorda E., Wei Y., Matarese G., Barnaba V., Piconese S. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc. Natl. Acad. Sci. USA, 2018, Vol. 115, no. 28, pp. E6546-E55.Pacella I., Procaccini C., Focaccetti C., Miacci S., Timperi E., Faicchia D., Severa M., Rizzo F., Coccia E.-M., Bonacina F., Mitro N., Norata G.-D., Rossetti G., Ranzani V., Pagani M., Giorda E., Wei Y., Matarese G., Barnaba V., Piconese S. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc. Natl. Acad. Sci. USA, 2018, Vol. 115, no. 28, pp. E6546-E55.Pellegrino M., del Bufalo F., de Angelis B., Quintarelli C., Caruana I., de Billy E. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. Cells, 2021, Vol. 10, no. 1, 14. doi: 10.3390/cells10010014.Pellegrino M., del Bufalo F., de Angelis B., Quintarelli C., Caruana I., de Billy E. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. Cells, 2021, Vol. 10, no. 1, 14. doi: 10.3390/cells10010014.Quintarelli C., Orlando D., Boffa I., Guercio M., Polito V.A., Petretto A., Lavarello C., Sinibaldi M., Weber G., Bufalo F.-D., Giorda E., Scarsella M., Petrini S., Pagliara D., Locatelli F., Angelis B.-D., Caruana I. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology, 2018, Vol. 7, no. 6, e1433518. doi: 10.1080/2162402X.2018.1433518.Quintarelli C., Orlando D., Boffa I., Guercio M., Polito V.A., Petretto A., Lavarello C., Sinibaldi M., Weber G., Bufalo F.-D., Giorda E., Scarsella M., Petrini S., Pagliara D., Locatelli F., Angelis B.-D., Caruana I. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology, 2018, Vol. 7, no. 6, e1433518. doi: 10.1080/2162402X.2018.1433518.Ramos C.A., Heslop H.E., Brenner M.K. CAR-T cell therapy for lymphoma. Ann. Rev. Med., 2016, Vol. 67, pp. 165-183.Ramos C.A., Heslop H.E., Brenner M.K. CAR-T cell therapy for lymphoma. Ann. Rev. Med., 2016, Vol. 67, pp. 165-183.Roex G., Timmers M., Wouters K., Campillo-Davo D., Flumens D., Schroyens W., Chu W., Berneman Z.-N., Lion E., Luo F., Anguille S.J. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J. Hematol. Oncol., 2020, Vol. 13, no. 1, pp. 1-14.Roex G., Timmers M., Wouters K., Campillo-Davo D., Flumens D., Schroyens W., Chu W., Berneman Z.-N., Lion E., Luo F., Anguille S.J. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J. Hematol. Oncol., 2020, Vol. 13, no. 1, pp. 1-14.Rompton J.G., Sukumar M., Roychoudhuri R., Clever D., Gros A., Eil RL., Tran E.,Hanada K.-I., Yu Z., Palmer D.-C., Kerkar S.-P., Michalek R.-D., Upham T., Leonardi A., Acquavella N., Wang E., Marincola F.-M., Gattinoni L., Muranski P., Sundrud M.-S., Klebanoff C.-A., Rosenberg S.-A., Fearon D.-T., Restifo N.-P. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristicsakt inhibition improves T-cell antitumor immunity. Cancer Res., 2015, Vol. 75, no. 2, pp. 296-305.Rompton J.G., Sukumar M., Roychoudhuri R., Clever D., Gros A., Eil RL., Tran E.,Hanada K.-I., Yu Z., Palmer D.-C., Kerkar S.-P., Michalek R.-D., Upham T., Leonardi A., Acquavella N., Wang E., Marincola F.-M., Gattinoni L., Muranski P., Sundrud M.-S., Klebanoff C.-A., Rosenberg S.-A., Fearon D.-T., Restifo N.-P. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristicsakt inhibition improves T-cell antitumor immunity. Cancer Res., 2015, Vol. 75, no. 2, pp. 296-305.Ron-Harel N., Santos D., Ghergurovich J.M., Sage P.T., Reddy A., Lovitch S.B., Dephoure N., Satterstrom F.-K., Sheffer M., Spinelli J.-B., Gygi S., Rabinowitz J.-D., Sharpe A.-H., Haigis M-C. Mitochondrial biogenesis and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab., 2016, Vol. 24, no. 1, pp. 104-117.Ron-Harel N., Santos D., Ghergurovich J.M., Sage P.T., Reddy A., Lovitch S.B., Dephoure N., Satterstrom F.-K., Sheffer M., Spinelli J.-B., Gygi S., Rabinowitz J.-D., Sharpe A.-H., Haigis M-C. Mitochondrial biogenesis and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab., 2016, Vol. 24, no. 1, pp. 104-117.Rosenberg S. CAR T cell receptor immunotherapy for patients with B-cell lymphoma. National Cancer Institute (NCI). Available at: https://clinicaltrials.gov/study/NCT00924326.Rosenberg S. CAR T cell receptor immunotherapy for patients with B-cell lymphoma. National Cancer Institute (NCI). Available at: https://clinicaltrials.gov/study/NCT00924326.Rostamian H., Fallah-Mehrjardi K., Khakpoor-Koosheh M., Pawelek J.M., Hadjati J., Brown C.E., Mirzaei H.-R. A metabolic switch to memory CAR T cells: Implications for cancer treatment. Cancer Lett., 2021, Vol. 500, pp. 107-118.Rostamian H., Fallah-Mehrjardi K., Khakpoor-Koosheh M., Pawelek J.M., Hadjati J., Brown C.E., Mirzaei H.-R. A metabolic switch to memory CAR T cells: Implications for cancer treatment. Cancer Lett., 2021, Vol. 500, pp. 107-118.Salmond R.J. mTOR regulation of glycolytic metabolism in T cells. Frontiers in Cell and Developmental Biology, 2018, Vol. 6:122.Salmond R.J. mTOR regulation of glycolytic metabolism in T cells. Frontiers in Cell and Developmental Biology, 2018, Vol. 6:122.Sanchez-Paulete A.R., Labiano S., Rodriguez-Ruiz M.E., Azpilikueta A., Etxeberria I., Bolaños E., Lang V., Rodriguez M., Aznar A.M., Jure-Kunkel M., Melero I. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur. J. Immunol., 2016, Vol. 46, no. 3, pp. 513-522.Sanchez-Paulete A.R., Labiano S., Rodriguez-Ruiz M.E., Azpilikueta A., Etxeberria I., Bolaños E., Lang V., Rodriguez M., Aznar A.M., Jure-Kunkel M., Melero I. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur. J. Immunol., 2016, Vol. 46, no. 3, pp. 513-522.Scharping N.E., Menk A.V., Moreci R.S., Whetstone R.D., Dadey R.E., Watkins S.C., Ferris R.-L., Delgoffe G.-M. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity, 2016, Vol. 45, no. 2, pp. 374-388.Scharping N.E., Menk A.V., Moreci R.S., Whetstone R.D., Dadey R.E., Watkins S.C., Ferris R.-L., Delgoffe G.-M. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity, 2016, Vol. 45, no. 2, pp. 374-388.Shen L., Xiao Y., Zhang C., Li S., Teng X., Cui L., Liu T., Wu N., Lu Z. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. Cancer Lett., 2022, Vol. 538, 215710. doi: 10.1016/j.canlet.2022.215710.Shen L., Xiao Y., Zhang C., Li S., Teng X., Cui L., Liu T., Wu N., Lu Z. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. Cancer Lett., 2022, Vol. 538, 215710. doi: 10.1016/j.canlet.2022.215710.Simula L., Campanella M., Campello S. Targeting Drp1 and mitochondrial fission for therapeutic immune modulation. Pharmacol. Res., 2019, Vol. 146, 104317. doi: 10.1016/j.phrs.2019.104317.Simula L., Campanella M., Campello S. Targeting Drp1 and mitochondrial fission for therapeutic immune modulation. Pharmacol. Res., 2019, Vol. 146, 104317. doi: 10.1016/j.phrs.2019.104317.Siska P.J., van der Windt G.J., Kishton R.J., Cohen S., Eisner W., MacIver N.J., Kater A.-P., Weinberg J.-B., Rathmell J.-C. Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J. Immunol., 2016, Vol. 197, no. 6, pp. 2532-2540.Siska P.J., van der Windt G.J., Kishton R.J., Cohen S., Eisner W., MacIver N.J., Kater A.-P., Weinberg J.-B., Rathmell J.-C. Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J. Immunol., 2016, Vol. 197, no. 6, pp. 2532-2540.Steentoft C., Migliorini D., King T.R., Mandel U., June C.H., Posey A.D. Jr. Glycan-directed CAR-T cells. Glycobiology, 2018, Vol. 28, no. 9, pp. 656-669.Steentoft C., Migliorini D., King T.R., Mandel U., June C.H., Posey A.D. Jr. Glycan-directed CAR-T cells. Glycobiology, 2018, Vol. 28, no. 9, pp. 656-669.Suarez E.R., Chang D.-K., Sun J., Sui J., Freeman G.J., Signoretti S., Zhu Q., Marasco W.-A. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget, 2016, Vol. 7, no. 23, 34341-34355.Suarez E.R., Chang D.-K., Sun J., Sui J., Freeman G.J., Signoretti S., Zhu Q., Marasco W.-A. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget, 2016, Vol. 7, no. 23, 34341-34355.Sukumar M., Kishton R.J., Restifo N.P. Metabolic Reprograming of anti-tumor immunity. Curr. Opin. Immunol., 2017, Vol. 46, pp. 14-22.Sukumar M., Kishton R.J., Restifo N.P. Metabolic Reprograming of anti-tumor immunity. Curr. Opin. Immunol., 2017, Vol. 46, pp. 14-22.Sukumar M., Liu J., Ji Y., Subramanian M., Crompton J.G.., Yu Z., Roychoudhuri R., Palmer D.-C., Muranski P., Karoly E.-D., Mohney R.-P., Klebanoff C.-A., Lal A., Finkel T., Restifo N.-P., Gattinoni L. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest., 2013, Vol. 123, no. 10, pp. 4479-4488.Sukumar M., Liu J., Ji Y., Subramanian M., Crompton J.G.., Yu Z., Roychoudhuri R., Palmer D.-C., Muranski P., Karoly E.-D., Mohney R.-P., Klebanoff C.-A., Lal A., Finkel T., Restifo N.-P., Gattinoni L. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest., 2013, Vol. 123, no. 10, pp. 4479-4488.Sukumar M., Liu J., Mehta G.U., Patel S.J., Roychoudhuri R., Crompton J.G., Klebanoff C.-A., Ji Y., Li P., Yu Z., Whitehill G.-D., Clever D., Eil R.-L., Palmer D.-C., Mitra S., Rao M., Keyvanfar K., Schrump D.-S., Wang E., Marincola F.-M., Gattinoni L., Leonard W.-J., Muranski P., Finkel T., Restifo N.-P. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab., 2016, Vol. 23, no. 1, pp. 63-76.Sukumar M., Liu J., Mehta G.U., Patel S.J., Roychoudhuri R., Crompton J.G., Klebanoff C.-A., Ji Y., Li P., Yu Z., Whitehill G.-D., Clever D., Eil R.-L., Palmer D.-C., Mitra S., Rao M., Keyvanfar K., Schrump D.-S., Wang E., Marincola F.-M., Gattinoni L., Leonard W.-J., Muranski P., Finkel T., Restifo N.-P. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab., 2016, Vol. 23, no. 1, pp. 63-76.Sukumar M., Roychoudhuri R., Restifo N.P. Nutrient competition: a new axis of tumor immunosuppression. Cell, 2015, Vol. 162, no. 6, pp. 1206-1208.Sukumar M., Roychoudhuri R., Restifo N.P. Nutrient competition: a new axis of tumor immunosuppression. Cell, 2015, Vol. 162, no. 6, pp. 1206-1208.Tang N., Cheng C., Zhang X., Qiao M., Li N., Mu W., Wei X.-F., Han W., Haoyi Wang H. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI insight, 2020, Vol. 5, no. 4, e133977. doi: 10.1172/jci.insight.133977.Tang N., Cheng C., Zhang X., Qiao M., Li N., Mu W., Wei X.-F., Han W., Haoyi Wang H. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI insight, 2020, Vol. 5, no. 4, e133977. doi: 10.1172/jci.insight.133977.Teijeira A., Labiano S., Garasa S., Etxeberria I., Santamaría E., Rouzaut A., Enamorado M., Azpilikueta A., Inoges S., Bolaños E., Aznar M.-A., Sánchez-Paulete A.-R., Sancho D., Melero I. Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) costimulation4-1BB (CD137) and mitochondria. Cancer Immunol. Res., 2018, Vol. 6, no. 7, pp. 798-811.Teijeira A., Labiano S., Garasa S., Etxeberria I., Santamaría E., Rouzaut A., Enamorado M., Azpilikueta A., Inoges S., Bolaños E., Aznar M.-A., Sánchez-Paulete A.-R., Sancho D., Melero I. Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) costimulation4-1BB (CD137) and mitochondria. Cancer Immunol. Res., 2018, Vol. 6, no. 7, pp. 798-811.Tokarew N., Ogonek J., Endres S., von Bergwelt-Baildon M., Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br. J. Cancer, 2019, Vol. 120, no. 1, pp. 26-37.Tokarew N., Ogonek J., Endres S., von Bergwelt-Baildon M., Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br. J. Cancer, 2019, Vol. 120, no. 1, pp. 26-37.Tsurutani N., Mittal P., Rose M.-C.S., Ngoi S.M., Svedova J., Menoret A., Treadway F.-B., Laubenbacher R., Suárez-Ramírez J.-E., Cauley L.-S., Adler A.-J.,Vella A.-T. Costimulation endows immunotherapeutic CD8 T cells with IL-36 responsiveness during aerobic glycolysis. J. Immunol., 2016, Vol. 196, no. 1, pp. 124-134.Tsurutani N., Mittal P., Rose M.-C.S., Ngoi S.M., Svedova J., Menoret A., Treadway F.-B., Laubenbacher R., Suárez-Ramírez J.-E., Cauley L.-S., Adler A.-J.,Vella A.-T. Costimulation endows immunotherapeutic CD8 T cells with IL-36 responsiveness during aerobic glycolysis. J. Immunol., 2016, Vol. 196, no. 1, pp. 124-134.van der Windt G.J., Everts B., Chang C.-H., Curtis J.-D., Tori C., Freitas T.-C., Amiel E., Pearce E.-I., Pearce E.-L. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity, 2012, Vol. 36, no. 1, pp. 68-78.van der Windt G.J., Everts B., Chang C.-H., Curtis J.-D., Tori C., Freitas T.-C., Amiel E., Pearce E.-I., Pearce E.-L. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity, 2012, Vol. 36, no. 1, pp. 68-78.van der Windt G.J., O’Sullivan D., Everts B., Huang S.C.-C., Buck M.D., Curtis J.D., Chang C.-H., Smith A.-M., Ai T., Faubert B., Jones R.-G., Pearce E.-J., Pearce E.-L. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc. Natl. Acad. Sci. USA, 2013, Vol. 110, no. 35, pp. 14336-14341.van der Windt G.J., O’Sullivan D., Everts B., Huang S.C.-C., Buck M.D., Curtis J.D., Chang C.-H., Smith A.-M., Ai T., Faubert B., Jones R.-G., Pearce E.-J., Pearce E.-L. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc. Natl. Acad. Sci. USA, 2013, Vol. 110, no. 35, pp. 14336-14341.Wan H., Xu B., Zhu N., Ren B. PGC-1α activator–induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer. Tumori, 2020, Vol. 106, no. 1, pp. 55-63.Wan H., Xu B., Zhu N., Ren B. PGC-1α activator–induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer. Tumori, 2020, Vol. 106, no. 1, pp. 55-63.Wei F., Wang D., Wei J., Tang N., Tang L., Xiong F., Guo C., Zhou M., Li X., Li G., Xiong W., Zhang S., Zeng Z. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. Cell. Mol. Life Sci., 2021, Vol. 78, no. 1, pp. 173-193.Wei F., Wang D., Wei J., Tang N., Tang L., Xiong F., Guo C., Zhou M., Li X., Li G., Xiong W., Zhang S., Zeng Z. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. Cell. Mol. Life Sci., 2021, Vol. 78, no. 1, pp. 173-193.Weinkove R., George P., Dasyam N., McLellan A.D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunology, 2019, Vol. 8, no. 5, e1049. doi: 10.1002/cti2.1049.Weinkove R., George P., Dasyam N., McLellan A.D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunology, 2019, Vol. 8, no. 5, e1049. doi: 10.1002/cti2.1049.Wu Y., Deng Z., Tang Y., Zhang S., Zhang Y.-Q. Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity. BMC Cancer, 2015, Vol. 15, no. 1, pp. 1-10.Wu Y., Deng Z., Tang Y., Zhang S., Zhang Y.-Q. Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity. BMC Cancer, 2015, Vol. 15, no. 1, pp. 1-10.Xiao C., Tian H., Zheng Y., Yang Z., Li S., Fan T., Xu J., Bai J., Liu J., Deng Z., Li C., He J. Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy. Front. Cell. Dev. Biol., 2022, Vol. 10, 1013885. doi: 10.3389/fcell.2022.1013885.Xiao C., Tian H., Zheng Y., Yang Z., Li S., Fan T., Xu J., Bai J., Liu J., Deng Z., Li C., He J. Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy. Front. Cell. Dev. Biol., 2022, Vol. 10, 1013885. doi: 10.3389/fcell.2022.1013885.Xu X., Gnanaprakasam J., Sherman J., Wang R. A metabolism toolbox for CAR T therapy. Front. Oncol., 2019, Vol. 9:322.Xu X., Gnanaprakasam J., Sherman J., Wang R. A metabolism toolbox for CAR T therapy. Front. Oncol., 2019, Vol. 9:322.Xu L., Fukumura D., Jain R.K. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J. Biol. Chem., 2002, Vol. 277, no. 13, pp. 11368-11374.Xu L., Fukumura D., Jain R.K. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J. Biol. Chem., 2002, Vol. 277, no. 13, pp. 11368-11374.Xu X., Gnanaprakasam J.R., Sherman J., Wang R. A metabolism toolbox for CAR T therapy. Front. Oncol., 2019, Vol. 9, 322. doi: 10.3389/fonc.2019.00322.Xu X., Gnanaprakasam J.R., Sherman J., Wang R. A metabolism toolbox for CAR T therapy. Front. Oncol., 2019, Vol. 9, 322. doi: 10.3389/fonc.2019.00322.Yang Q., Hao J., Chi M., Wang Y., Xin B., Huang J., Lu J., Li J., Sun X., Li C., Huo H., Zhang J., Han Y., Guo C. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology, 2022, Vol. 11, no. 1, 2055703. doi: 10.1080/2162402X.2022.2055703.Yang Q., Hao J., Chi M., Wang Y., Xin B., Huang J., Lu J., Li J., Sun X., Li C., Huo H., Zhang J., Han Y., Guo C. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology, 2022, Vol. 11, no. 1, 2055703. doi: 10.1080/2162402X.2022.2055703.Yang W., Bai Y., Xiong Y., Zhang J., Chen S., Zheng X., Meng X., Lunyi Li L., Wang J., Xu C., Yan C., Wang L., Chang C.-C.Y., Chang T.-Y., Zhang T., Zhou P., Song B.-L., Liu W., Sun S.-C., Liu X., Li B.-I., Xu C. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature, 2016, Vol. 531, no. 7596, pp. 651-655.Yang W., Bai Y., Xiong Y., Zhang J., Chen S., Zheng X., Meng X., Lunyi Li L., Wang J., Xu C., Yan C., Wang L., Chang C.-C.Y., Chang T.-Y., Zhang T., Zhou P., Song B.-L., Liu W., Sun S.-C., Liu X., Li B.-I., Xu C. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature, 2016, Vol. 531, no. 7596, pp. 651-655.Ye L., Park J.J., Peng L., Yang Q., Chow R.D., Dong M.B., Lam S.-Z., Guo J., Tang E., Zhang Y., Wang G., Dai X., Du Y., Kim H.-R., Cao H., Errami Y., Clark P., Bersenev A., Montgomery R.-R., Chen S. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab., 2022, Vol. 34, no. 4, pp. 595-614.e14.Ye L., Park J.J., Peng L., Yang Q., Chow R.D., Dong M.B., Lam S.-Z., Guo J., Tang E., Zhang Y., Wang G., Dai X., Du Y., Kim H.-R., Cao H., Errami Y., Clark P., Bersenev A., Montgomery R.-R., Chen S. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab., 2022, Vol. 34, no. 4, pp. 595-614.e14.Yu W., Lei Q., Yang L., Qin G., Liu S., Wang D., Ping Y., Zhang Y. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J. Hematol. Oncol., 2021, Vol. 14, no. 1, pp. 1-19.Yu W., Lei Q., Yang L., Qin G., Liu S., Wang D., Ping Y., Zhang Y. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J. Hematol. Oncol., 2021, Vol. 14, no. 1, pp. 1-19.Zeng H., Cohen S., Guy C., Shrestha S., Neale G., Brown S.A., Caryn Cloer C., Kishton R.-J., Gao X., Youngblood B., Do M., Li M.-O., Locasale J.-W., Rathmell J.-C., Chi H. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular helper T cell differentiation. Immunity, 2016, Vol. 45, no. 3, pp. 540-554.Zeng H., Cohen S., Guy C., Shrestha S., Neale G., Brown S.A., Caryn Cloer C., Kishton R.-J., Gao X., Youngblood B., Do M., Li M.-O., Locasale J.-W., Rathmell J.-C., Chi H. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular helper T cell differentiation. Immunity, 2016, Vol. 45, no. 3, pp. 540-554.Zhang L., Li W. Rewiring mitochondrial metabolism for CD8+ T cell memory formation and effective cancer immunotherapy. Front. Immunol., 2020, Vol. 11, 1834. doi: 10.3389/fimmu.2020.01834.Zhang L., Li W. Rewiring mitochondrial metabolism for CD8+ T cell memory formation and effective cancer immunotherapy. Front. Immunol., 2020, Vol. 11, 1834. doi: 10.3389/fimmu.2020.01834.Zhang M., Jin X., Sun R., Xiong X., Wang J., Xie D., Zhao M.-F. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J. Transl. Med., 2021, Vol. 19, no. 1, pp. 1-11.Zhang M., Jin X., Sun R., Xiong X., Wang J., Xie D., Zhao M.-F. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J. Transl. Med., 2021, Vol. 19, no. 1, pp. 1-11.Zhang Q., Ding J., Sun S., Liu H., Lu M., Wei X., Gao X., Zhang X., Fu Q., Zheng Z. Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy. Am. J. Cancer Res., 2019, Vol. 9, no. 11, 2379-2396.Zhang Q., Ding J., Sun S., Liu H., Lu M., Wei X., Gao X., Zhang X., Fu Q., Zheng Z. Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy. Am. J. Cancer Res., 2019, Vol. 9, no. 11, 2379-2396.Zhang T., Zhang Z., Li F., Ping Y., Qin G., Zhang C., Zhang Y. miR-143 regulates memory T cell differentiation by reprogramming T Cell Metab. J. Immunol., 2018, Vol. 201, no. 7, pp. 2165-2175.Zhang T., Zhang Z., Li F., Ping Y., Qin G., Zhang C., Zhang Y. miR-143 regulates memory T cell differentiation by reprogramming T Cell Metab. J. Immunol., 2018, Vol. 201, no. 7, pp. 2165-2175.Zhang Z., Zhang C., Li F., Zhang B., Zhang Y. Regulation of memory CD8+ T cell differentiation by microRNAs. Cell. Physiol. Biochem., 2018, Vol. 47, no. 6, pp. 2187-2198.Zhang Z., Zhang C., Li F., Zhang B., Zhang Y. Regulation of memory CD8+ T cell differentiation by microRNAs. Cell. Physiol. Biochem., 2018, Vol. 47, no. 6, pp. 2187-2198.Zheng W., O’Hear C.E., Alli R., Basham J.H., Abdelsamed H.A., Palmer L.E., Jones L.-L., Youngblood B., Geiger T.-L. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia, 2018, Vol. 32, no. 5, pp. 1157-1167.Zheng W., O’Hear C.E., Alli R., Basham J.H., Abdelsamed H.A., Palmer L.E., Jones L.-L., Youngblood B., Geiger T.-L. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia, 2018, Vol. 32, no. 5, pp. 1157-1167.Zheng W., O’Hear C.E., Alli R., Basham J.H., Abdelsamed H.A., Palmer L.E., Jones L.-L., Youngblood B., Geiger T.-L. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia, 2018, Vol. 32, no. 5, pp. 1157-1167.Zheng W., O’Hear C.E., Alli R., Basham J.H., Abdelsamed H.A., Palmer L.E., Jones L.-L., Youngblood B., Geiger T.-L. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia, 2018, Vol. 32, no. 5, pp. 1157-1167.

The authors declare that there are no conflicts of interest present.